Current treatment guidelines recommend using cancer antigen-125 (CA-125) as a diagnostic marker for ovarian cancer recurrence, but a recent study suggests CA-125 has poor concordance with progressive ...

Current CA-125 thresholds may miss ovarian cancer in racially diverse patients, delaying treatment initiation and contributing to health disparities. Original CA-125 studies were conducted on ...

The likelihood of having an elevated CA-125 level at ovarian cancer diagnosis was lower for American Indian, Asian, or Black patients versus White patients. HealthDay News — Black and American Indian ...

Cancer Antigen 125 (CA-125) testing shows 23% lower odds of elevated levels in American Indian and Black patients with ovarian cancer compared with White patients. Patients with false-negative CA-125 ...

Histologic Grade, But Not SYT-SSX Fusion Type, Is an Important Prognostic Factor in Patients With Synovial Sarcoma: A Multicenter, Retrospective Analysis From a single-institution registry of 527 ...

A common blood test may miss ovarian cancer in some Black and Native American patients, delaying their treatment, a new study finds. It’s the latest example of medical tests that contribute to health ...

Differential CD146 Expression on Circulating Versus Tissue Endothelial Cells in Rectal Cancer Patients: Implications for Circulating Endothelial and Progenitor Cells As Biomarkers for Antiangiogenic ...

“[...] these inexpensive, widely available tests with rapid turnaround times and relatively short half-lives (CEA, CA-125, and CA19-9) are perfectly situated to ...

While the human epididymis protein 4 (HE4) has been previously identified as a blood biomarker of fibrosis, the relationship HE4 has with other blood biomarkers has not been established.